IMPI: No Immunotherapy Benefit in Tuberculous PericarditisIMPI: No Immunotherapy Benefit in Tuberculous Pericarditis

Although prednisolone might be appropriate in some patients, the authors propose, neither the glucocorticoid nor M indicus pranii immunotherapy improved survival in the 1400-patient trial. Heartwire
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news